Search

At a noncytotoxic concentration, emetine was found to inhibit replication of DNA viruses [buffalopoxvirus (BPXV) and bovine herpesvirus 1 (BHV-1)] as well as RNA viruses [peste des petits ruminants virus (PPRV) and Newcastle disease virus (NDV)]. Using the time-of-addition and virus step-specific assays, we showed that emetine treatment resulted in reduced synthesis of viral RNA (PPRV and NDV) and DNA (BPXV and BHV-1) as well as inhibiting viral entry (NDV and BHV-1). In addition, emetine treatment also resulted in decreased synthesis of viral proteins. In a cell free endogenous viral polymerase assay, emetine was found to significantly inhibit replication of NDV, but not BPXV genome, suggesting that besides directly inhibiting specific viral polymerases, emetine may also target other factors essentially required for efficient replication of the viral genome. Moreover, emetine was found to significantly inhibit BPXV-induced pock lesions on chorioallantoic membrane (CAM) along with associated mortality of embryonated chicken eggs. At a lethal dose 50 (LD 50 ) of 126.49 ng/egg and at an effective concentration 50 (EC 50 ) of 3.03 ng/egg, the therapeutic index of the emetine against BPXV was determined to be 41.74. Emetine was also found to significantly delay NDV-induced mortality in chicken embryos associated with reduced viral titers. Further, emetine-resistant mutants were not observed upon long-term (P = 25) sequential passage of BPXV and NDV in cell culture. Collectively, we have extended the effective antiviral activity of emetine against diverse groups of DNA and RNA viruses and propose that emetine could provide significant therapeutic value against some of these viruses without inducing an antiviral drug-resistant phenotype. [ABSTRACT FROM AUTHOR]

In the present study, we evaluated the antiviral efficacy of the silver nanoparticles (SNPs) against Peste des petits ruminants virus (PPRV), a prototype Morbillivirus. The leaf extract of the Argemone maxicana was used as a reducing agent for biological synthesis of the SNPs from silver nitrate. The SNPs were characterized using UV-vis absorption spectroscopy, X-ray diffraction (XRD) and transmission electron microscopy (TEM). The TEM analysis revealed particle size of 5-30 nm and the XRD analysis revealed their characteristic silver structure. The treatment of Vero cells with the SNPs at a noncytotoxic concentration significantly inhibited PPRV replication in vitro. The time-course and virus step-specific assays showed that the SNPs impair PPRV replication at the level of virus entry. The TEM analysis showed that the SNPs interact with the virion surface as well with the virion core. However, this interaction has no direct virucidal effect, instead exerts a blocking effect on viral entry into the target cells. This is the first documented evidence indicating that the SNPs are capable of inhibiting a Morbillivirus replication in vitro. [ABSTRACT FROM AUTHOR]

We describe herein that Apigenin, which is a dietary flavonoid, exerts a strong in vitro and in ovo antiviral efficacy against buffalopox virus (BPXV). Apigenin treatment was shown to inhibit synthesis of viral DNA, mRNA and proteins, without affecting other steps of viral life cycle such as attachment, entry and budding. Although the major mode of antiviral action of Apigenin was shown to be mediated via targeting certain cellular factors, a modest inhibitory effect of Apigenin was also observed directly on viral polymerase. We also evaluated the selection of drug-resistant virus variants under long-term selection pressure of Apigenin. Wherein Apigenin-resistant mutants were not observed up to ~ P20 (passage 20), a significant resistance was observed to the antiviral action of Apigenin at ~ P30. However, a high degree resistance could not be observed even up to P60. To the best of our knowledge, this is the first report describing in vitro and in ovo antiviral efficacy of Apigenin against poxvirus infection. The study also provides mechanistic insights on the antiviral activity of Apigenin and selection of potential Apigenin-resistant mutants upon long-term culture. • Apigenin exhibits in vitro and in ovo antiviral activity against BPXV. • Apigenin targets cellular ERK/MNK1/eIF4E signaling to block BPXV protein synthesis. • Apigenin may also directly act to inhibit viral polymerase activity. • Generation of Apigenin-resistant viral mutants may not be an unprecedent event at higher passage. [ABSTRACT FROM AUTHOR]